Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), released its Sustainability Report 2023.
HYDERABAD, India, Feb. 01, 2024 (GLOBE NEWSWIRE) -- To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global...
HYDERABAD, India, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), entered its Silver Jubilee year with...
HYDERABAD, India, June 22, 2023 (GLOBE NEWSWIRE) -- To help combat climate change, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced...
HYDERABAD, India, June 06, 2023 (GLOBE NEWSWIRE) -- On the World Environment Day 2023, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO),...
HYDERABAD, India, April 20, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced the opening of Sai Schrödinger Research Laboratories (SSRL) at its R&D campus in Hyderabad, India. The facility was inaugurated by Dr. Karen Akinsanya, President of R&D, Therapeutics at Schrödinger Inc., in the presence of members of the leadership team of Schrödinger and Sai Life Sciences.
MANCHESTER, England and HYDERABAD, India, March 15, 2023 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO), today announced the setting up of a GMP Kilo Lab at its facility in Alderley Park, Manchester, UK. The new GMP Kilo Lab will enable Sai Life Sciences to offer drug substance and intermediates supplies ranging from gram to kilogram quantities to meet customer clinical requirements at an accelerated pace.
Private equity investor TPG Capital is looking to exit its five-year-old investment in Hyderabad-based Sai Life Sciences, a pharmaceutical contract development and manufacturing organisation (CDMO), according to three people aware of the development, a move that could fetch the PE firm as much as $500 million for its minority stake in the company.
Sai Life Sciences, one of India's fastest growing contract research, development and manufacturing organizations (CRO-CDMO), has opened a new high-potency API (HPAPI) manufacturing facility at its cGMP API manufacturing campus in Bidar, India. The addition of this new facility expands the company's expertise across HPAPI development and manufacturing, providing its customers with a streamlined pathway for NCE development.
Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.